Yuichi Kawata

1.3k total citations · 2 hit papers
21 papers, 873 citations indexed

About

Yuichi Kawata is a scholar working on Pathology and Forensic Medicine, Immunology and Neurology. According to data from OpenAlex, Yuichi Kawata has authored 21 papers receiving a total of 873 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Pathology and Forensic Medicine, 8 papers in Immunology and 7 papers in Neurology. Recurrent topics in Yuichi Kawata's work include Multiple Sclerosis Research Studies (12 papers), Peripheral Neuropathies and Disorders (6 papers) and Immunotherapy and Immune Responses (6 papers). Yuichi Kawata is often cited by papers focused on Multiple Sclerosis Research Studies (12 papers), Peripheral Neuropathies and Disorders (6 papers) and Immunotherapy and Immune Responses (6 papers). Yuichi Kawata collaborates with scholars based in Japan, United States and France. Yuichi Kawata's co-authors include Benjamin Greenberg, Takashi Yamamura, Pádraig Wright, J. de Sèze, Beata Zakrzewska‐Pniewska, Albert Saiz, Ingo Kleiter, Jacqueline Palace, Francesco Patti and Kazuo Fujihara and has published in prestigious journals such as New England Journal of Medicine, Neurology and The Lancet Neurology.

In The Last Decade

Yuichi Kawata

21 papers receiving 857 citations

Hit Papers

Trial of Satralizumab in Neuromyelitis Optica Spectrum Di... 2019 2026 2021 2023 2019 2020 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder
    2019 415 citations Takashi Yamamura, Ingo Kleiter et al. New England Journal of Medicine profile →
  2. Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial
    2020 317 citations Anthony Traboulsee, Benjamin Greenberg et al. The Lancet Neurology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Yuichi Kawata Japan 8 616 568 178 171 92 21 873
Metha Apiwattanakul Thailand 12 655 1.1× 651 1.1× 214 1.2× 101 0.6× 110 1.2× 44 900
Kyoichi Nomura Japan 12 406 0.7× 449 0.8× 156 0.9× 117 0.7× 86 0.9× 34 700
Xiaonan Zhong China 20 602 1.0× 451 0.8× 207 1.2× 266 1.6× 221 2.4× 46 1.0k
Sei Hayakawa Japan 10 588 1.0× 461 0.8× 190 1.1× 163 1.0× 112 1.2× 14 751
Saif Huda United Kingdom 18 382 0.6× 795 1.4× 120 0.7× 86 0.5× 80 0.9× 56 1.0k
Hayato Yamazaki Japan 10 366 0.6× 311 0.5× 211 1.2× 113 0.7× 47 0.5× 14 602
Reinhard Reuß Germany 9 422 0.7× 337 0.6× 151 0.8× 73 0.4× 88 1.0× 14 573
M. Cossburn United Kingdom 10 495 0.8× 241 0.4× 150 0.8× 174 1.0× 75 0.8× 17 687
Héctor Perkal Spain 14 617 1.0× 286 0.5× 205 1.2× 109 0.6× 171 1.9× 19 873
Tania Kuempfel Germany 10 406 0.7× 352 0.6× 128 0.7× 136 0.8× 50 0.5× 18 575

Countries citing papers authored by Yuichi Kawata

Since Specialization
Citations

This map shows the geographic impact of Yuichi Kawata's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yuichi Kawata with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yuichi Kawata more than expected).

Fields of papers citing papers by Yuichi Kawata

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yuichi Kawata. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yuichi Kawata. The network helps show where Yuichi Kawata may publish in the future.

Co-authorship network of co-authors of Yuichi Kawata

This figure shows the co-authorship network connecting the top 25 collaborators of Yuichi Kawata. A scholar is included among the top collaborators of Yuichi Kawata based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yuichi Kawata. Yuichi Kawata is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Kinugasa, Eriko, Ken Igawa, Hisaki Shimada, et al.. (2021). Anti-pruritic effect of nemolizumab in hemodialysis patients with uremic pruritus: a phase II, randomized, double-blind, placebo-controlled clinical study. Clinical and Experimental Nephrology. 25(8). 875–884. 29 indexed citations
3.
Yamamura, Tomohiko, Ingo Kleiter, Jacqueline Palace, et al.. (2020). Efficacy of Satralizumab (SA237) in Subgroups of Patients in SakuraSky: A Phase III Double-Blind, Placebo-Controlled, Add-On Study in Patients with Neuromyelitis Optica Spectrum Disorder (NMOSD). Multiple Sclerosis Journal. 26. 1 indexed citations
4.
Suzuki, Takao, Atsushi Harada, Hiroyuki Shimada, et al.. (2020). Assessment of eldecalcitol and alendronate effect on postural balance control in aged women with osteoporosis. Journal of Bone and Mineral Metabolism. 38(6). 859–867. 6 indexed citations
5.
Traboulsee, Anthony, Benjamin Greenberg, Jeffrey L. Bennett, et al.. (2020). Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial. The Lancet Neurology. 19(5). 402–412. 317 indexed citations breakdown →
6.
Bennett, Jeffrey L., Benjamin Greenberg, Anthony Traboulsee, et al.. (2020). Efficacy of Satralizumab As Monotherapy in Pre-Specified Subgroups of Sakurastar, a Double-Blind Placebo-Controlled Phase 3 Clinical Study in Patients with Neuromyelitis Optica Spectrum Disorder (NMOSD). Multiple Sclerosis and Related Disorders. 37. 101576–101576. 1 indexed citations
7.
Hašková, Zdenka, Benjamin Frishberg, J. de Sèze, et al.. (2020). Efficacy and safety of satralizumab from two phase 3 trials in neuromyelitis optica spectrum disorder. 61(7). 3173–3173. 1 indexed citations
8.
Sèze, J. de, Brian G. Weinshenker, Yusuke Terada, et al.. (2020). Efficacy and Safety of Satralizumab for Relapse Prevention in Neuromyelitis Optica Spectrum Disorder: A Pooled Analysis from Two Phase 3 Clinical Trials. Multiple Sclerosis and Related Disorders. 37. 101592–101592. 2 indexed citations
9.
Yamamura, Takashi, Ingo Kleiter, Kazuo Fujihara, et al.. (2019). Efficacy of satralizumab in subgroups of patients in SAkuraSky: A phase III double-blind, placebo-controlled, add-on study in patients with neuromyelitis optica spectrum disorder (NMOSD). Journal of the Neurological Sciences. 405. 11–12. 3 indexed citations
10.
Yamamura, Takashi, Ingo Kleiter, Kazuo Fujihara, et al.. (2019). Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder. New England Journal of Medicine. 381(22). 2114–2124. 415 indexed citations breakdown →
11.
Traboulsee, Anthony, Benjamin Greenberg, Jeffrey Bennett, et al.. (2019). Efficacy and safety of satralizumab monotherapy for relapse prevention in neuromyelitis optica spectrum disorder (NMOSD): Results from SAkuraStar, a double-blind placebo-controlled phase 3 clinical study. Journal of the Neurological Sciences. 405. 171–171. 11 indexed citations
12.
13.
Sèze, J. de, Ingo Kleiter, Jacqueline Palace, et al.. (2018). A double-blind placebo-controlled study of satralizumab (SA237), a recycling anti-IL-6 receptor monoclonal antibody, as add-on therapy for neuromyelitis optica spectrum disorder (NMOSD). Multiple Sclerosis Journal. 24. 985–986. 5 indexed citations
14.
Kleiter, Ingo, Jacqueline Palace, Benjamin Greenberg, et al.. (2018). A double-blind placebo-controlled study of satralizumab (SA237), a recycling anti-IL-6 receptor monoclonal antibody, as add-on therapy for neuromyelitis optica (NMO) and NMO spectrum disorder (NMOSD). European Journal of Neurology. 25. 536–536. 1 indexed citations
15.
Li, Pu, Teruhiko Koike, Haiying Jiang, et al.. (2012). Acute Treatment with Candesartan Cilexetil, an Angiotensin II Type 1 Receptor Blocker, Improves Insulin Sensitivity in High-Fructose-Diet-fed Rats. Hormone and Metabolic Research. 44(4). 286–290. 7 indexed citations
16.
Koike, Taisuke, et al.. (2010). Combined Effects of Short-term Calorie Restriction and Exercise on Insulin Action in Normal Rats. Hormone and Metabolic Research. 42(13). 950–954. 13 indexed citations
17.
Yamazaki, Y., Mikio Doy, Nobuhiko Okabe, et al.. (2009). Serological survey of avian H5N2-subtype influenza virus infections in human populations. Archives of Virology. 154(3). 421–427. 16 indexed citations
18.
Kubota, Masashi, et al.. (2008). Effects of Continuous Low-carbohydrate Diet after Long-term Exercise on GLUT-4 Protein Content in Rat Skeletal Muscle. Hormone and Metabolic Research. 40(1). 24–28. 2 indexed citations
19.
Koike, Teruhiko, et al.. (2008). A High-fructose Diet Impairs Akt and PKCζ Phosphorylation and GLUT4 Translocation in Rat Skeletal Muscle. Hormone and Metabolic Research. 40(8). 528–532. 20 indexed citations
20.
Shimizu, Shinichi, Yuichi Kawata, Norito Kawakami, & Hideyasu Aoyama. (2001). Effects of changes in obesity and exercise on the development of diabetes and return to normal fasting plasma glucose levels at one-year follow-up in middle-aged subjects with impaired fasting glucose. Environmental Health and Preventive Medicine. 6(2). 127–131. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Metha Apiwattanakul Breakdown of academic impact, for papers by Kyoichi Nomura Breakdown of academic impact, for papers by Xiaonan Zhong Breakdown of academic impact, for papers by Sei Hayakawa Breakdown of academic impact, for papers by Saif Huda Breakdown of academic impact, for papers by Hayato Yamazaki Breakdown of academic impact, for papers by Reinhard Reuß Breakdown of academic impact, for papers by M. Cossburn Breakdown of academic impact, for papers by Héctor Perkal Breakdown of academic impact, for papers by Tania Kuempfel
Rankless by CCL
2026